TJ Madsen is among the founding members of the New Herald Tribune and chairs the editorial board. He worked for national syndicated newspapers in Newark, Philadelphia, and Baltimore before moving to the midwest.
August 15 , 2024
Washington, D.C. – In a historic move aimed at reducing the financial burden on millions of Americans, the Biden-Harris Administration has successfully negotiated lower prices for several high-cost medications, including ketamine. This landmark agreement marks the first time Medicare has directly negotiated drug prices with pharmaceutical companies, a significant shift in policy that promises substantial savings for both the government and Medicare beneficiaries.
The negotiations, which concluded earlier this month, have resulted in price reductions ranging from 38% to 79% for ten of the most expensive and frequently prescribed drugs under Medicare. These medications, used to treat conditions such as diabetes, heart disease, and certain cancers, are critical for the health and well-being of millions of older Americans.
Ketamine, known for its use in treating severe depression and chronic pain, is among the drugs that will see a significant price drop. This is expected to make the medication more accessible to patients who rely on it for managing their conditions.
The new prices, set to take effect on January 1, 2026, are projected to save Medicare an estimated $6 billion annually. Additionally, out-of-pocket costs for Medicare beneficiaries are expected to decrease by approximately $1.5 billion in 2026 alone1. These savings come at a crucial time, as many Americans continue to face financial challenges due to rising healthcare costs.
“Americans pay too much for their prescription drugs. That makes today’s announcement historic,” said U.S. Department of Health and Human Services Secretary Xavier Becerra. "For the first time ever, Medicare negotiated directly with drug companies, and the American people are better off for it."
CMS Administrator Chiquita Brooks-LaSure echoed these sentiments, highlighting the broader implications of the negotiations. "These negotiations will not only lower the prices of critically important medications but will also save billions of dollars, demonstrating our commitment to lowering healthcare and prescription drug costs for Americans."
This development is part of a broader effort by the Biden-Harris Administration to make healthcare more affordable and accessible. In addition to the negotiated drug prices, the Inflation Reduction Act has already begun to lower drug costs for Medicare recipients. Starting next year, all Medicare Part D enrollees will benefit from a $2,000 cap on their annual out-of-pocket prescription drug costs."
As the new prices take effect, millions of Americans can look forward to more affordable access to essential medications, marking a significant step forward in the fight against high drug prices.
Copyright © 2026. All rights reserved.